uniQure (QURE) Net Income towards Common Stockholders (2016 - 2026)

uniQure (QURE) recorded quarterly Net Income towards Common Stockholders of -$53.5 million in Q1 2026, down 187.14% quarter-over-quarter from -$18.6 million in Q4 2025, and down 22.68% on a YoY basis from -$69.2 million in Q1 2025.

uniQure (QURE) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends

uniQure's Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at -$53.5 million for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders fell 22.68% year-over-year to -$53.5 million; the TTM figure through Mar 2026 stood at -$189.3 million (up 12.99% YoY), while the FY2025 annual figure was -$199.0 million, up 16.94% from the prior year.
  • Net Income towards Common Stockholders was -$53.5 million for Q1 2026 at uniQure, down from -$18.6 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $6.8 million in Q4 2022 to a low of -$89.6 million in Q3 2023.
  • Historically, Net Income towards Common Stockholders has averaged -$53.4 million across 5 years, with a median of -$53.5 million in 2026.
  • The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders sank 1175.45% in 2023, then surged 74.55% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $6.8 million in 2022, then tumbled by 1175.45% to -$73.2 million in 2023, then dropped by 0.08% to -$73.3 million in 2024, then soared by 74.55% to -$18.6 million in 2025, then plunged by 187.14% to -$53.5 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$53.5 million (Q1 2026), -$18.6 million (Q4 2025), and -$79.4 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -13.56 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 2.50 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.63 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 uniQure 2.88 Bn 2.88 Bn 3.34 Mn -53.54 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -53.54 Mn
Dec 31, 2025 -18.64 Mn
Sep 30, 2025 -79.42 Mn
Jun 30, 2025 -37.72 Mn
Mar 31, 2025 -43.64 Mn
Dec 31, 2024 -73.26 Mn
Sep 30, 2024 -44.38 Mn
Jun 30, 2024 -56.30 Mn
Mar 31, 2024 -65.62 Mn
Dec 31, 2023 -73.21 Mn
Sep 30, 2023 -89.57 Mn
Jun 30, 2023 -68.47 Mn
Mar 31, 2023 -77.23 Mn
Dec 31, 2022 6.81 Mn
Sep 30, 2022 -47.86 Mn
Jun 30, 2022 -39.06 Mn
Mar 31, 2022 -46.68 Mn
Dec 31, 2021 8.21 Mn
Sep 30, 2021 -36.53 Mn
Jun 30, 2021 399.47 Mn